Aliko Scientific: Shareholders’ Meeting appoints Francesco Trisolini as Group CEO and for implementation of the approved industrial plan

About this update from Ikonisys Sa

Hospitex Ikonisys Aliko Scientific: Shareholders' Meeting appoints Francesco Trisolini as Group CEO and for implementation of the approved industrial plan 17/02/2026 Paris, 17/02/2026 - Aliko Scientific SA (formerly Ikonisys SA - Ticker: ALIKO), following the recent capital increase and the renewal of the Board of Directors, announces that the Shareholders' Meeting has resolved to appoint Francesco Trisolini as Chief Executive Officer of the Group and formally was given him mandate to implement the Group's industrial plan. The industrial plan, presented by Francesco Trisolini to the Board of Directors and shareholders, was approved by the Shareholders' Meeting and forms the foundation of the Group's new strategic positioning. The appointment of Mr. Trisolini as Group CEO reflects the confidence expressed by both the Board and shareholders in his strategic vision, proven managerial competence, and ability to manage complex transformation processes. Francesco Trisolini previously served as CEO of the Group's subsidiary Hospitex , where he played a key role in strengthening the company's industrial positioning and in driving the integration process that led to the creation of Aliko Scientific as an integrated player in oncology diagnostics . Completion of strategic repositioning and Group reorganization As a first step to fully execute the approved industrial plan, the Shareholders' Meeting resolved to change the corporate name of the parent company from Ikonisys SA to Aliko Scientific SA , as well as the corporate name of the subsidiary Ikonisys Srl to Aliko Scientific Srl. Aliko Scientific Srl will act as the Business Unit responsible for coordinating the Group's corporate functions , including administration and control, marketing, commercial activities, regulatory affairs, quality, intellectual property rights (IPR), human resources, and IT. This organizational structure is designed to increase operational efficiency , reduce costs, and enhance overall productivity in support of the Group's growth objectives. Industrial plan based on three strategic pillars The approved industrial plan is structured around three core strategic pillars . The first pillar focuses on strengthening the Group's commercial governance , with the objective of accelerating the expansion of the global distributor network, replicating successful partnership models already implemented, including the collaboration with Menarini Diagnostics in Italy . The second pillar involves the evaluation of selective M&A targeting small and medium-sized enterprises operating in the oncology diagnostics sector , aimed at expanding and integrating the Group's product portfolio and reinforcing its technological positioning. The third pillar consists of the continuation and reinforcement of internal research and development activities , focused on the launch of new innovative products in oncology diagnostics. Particular emphasis will be placed on the integration of the Group's technologies and the development of a comprehensive and interoperable oncology diagnostic ecosystem . Francesco Trisolini, newly appointed Group CEO, commented : "I would like to thank the Board of Directors and the shareholders for the trust placed in me and for approving the industrial plan I presented. The mandate to implement this plan allows us to execute a clear and ambitious strategy focused on the integration of oncology diagnostic technologies, international commercial expansion, and the creation of sustainable long-term industrial value." About ALIKO SCIENTIFIC (Ikonisys SA) Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to advancing oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC's mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic investments to create a global center of excellence in oncology. For more information, visit: https://www.alikoscientific.com About IKONISYS Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes. For more information, visit: https://www.ikonisys.com About HOSPITEX Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research, development, and production, thus ensuring the highest standards of quality. Hospitex offers the world's most advanced Liquid-Based Cytology (LBC) technology, capable of processing any cytological sample with unmatched precision. Hospitex is uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative future in cytology diagnostics. For more information, visit: https://www.hospitex.com CONTACTS Ikonisys Alessandro Mauri, CFO [email protected] NewCap Louis-Victor Delouvrier/Aurélie Manavarere, Investor Relations [email protected] Tel. +33 (0)1 44 71 94 94 NewCap Arthur Rouillé, Media Relations [email protected] Tel. +33 (0)1 44 71 00 15 Download the pdf Shareholders' Meeting WHX Labs previous Aliko Scientific at WHX Labs 2026 in Dubai

View stock analysis, news, and events for Ikonisys Sa